BRCA-1、ERCCmRNA表达水平与在大肠癌铂类化疗预后的相关性研究  

The relationship between BRCA-1、ERCCmRNA expression level and prognosis platinum-based chemotherapy in colorectal cancer

作　　者：刘燕文[1] 鲁凯[1] 贾建英[1] 叶红玲[1] 姜维美[1] 

机构地区：[1]连云港市第二人民医院肿瘤内科,江苏连云港222023

出　　处：《中国实验诊断学》2013年第10期1806-1810,共5页Chinese Journal of Laboratory Diagnosis

基　　金：江苏省连云港市科技局资助项目(SH0907);蚌埠医学院科研基金资助项目(BY0953)

摘　　要：目的探讨以铂类为基础化疗方案的大肠癌患者中乳腺癌敏感蛋白Ⅰ型(BRCA-1)、核苷酸切除修复交叉互补基因(ERCC-1)表达与患者临床病理特征的关系及其预后意义。方法采用实时荧光定量逆转录聚合酶联反应(RT-qPCR)检测54例大肠癌患者组织标本中BRCA-1、ERCCmRNA表达,比较其表达水平与患者临床病理特征和生存时间之间的关系。结果 (1)BRCA-1mRNA低表达20例(37.04%),高表达34例(62.97%)。BRCA-1mRNA表达水平与淋巴结转移及临床分期有关(P=0.037,P=0.034);(2)BRCA-1mRNA低表达患者中位生存时间MST(47.84月)高于高表达患者(35.36月,P=0.137);(3)BRCA-1mRNA表达在16例晚期大肠癌患者中总生存时间高表达患者(32.6月)长于低表达患者(9.5月,P=0.026);至肿瘤进展时间高表达患者(10.3月)长于低表达患者(4.3月,P=0.026);(4)ERCCmRNA低表达14例(25.93%),高表达40例(74.07%)。ERCCmRNA表达水平与临床病理特征无关(P>0.05);(5)ERCCmRNA低表达患者中位生存时间MST(49.50月)高于低表达患者(30.33月,P=0.014);(6)ERCCmRNA表达在16例晚期大肠癌患者中总生存时间低表达患者(41.1月)长于高表达患者(20.7月P=0.018);至肿瘤进展时间高表达患者(9.5月)长于低表达患者(8.9月,P=0.966);(7)ERCC与BRCA-1表达有相关性,(r=0.497 P<0.05);(8)COX多因素分析显示ERCCmRNA表达水平可以作为大肠癌患者铂类化疗预后的独立预测指标。结论 ERCC1mRNA表达水平的高低与大肠癌患者铂类化疗生存时间存在显著相关性,可以作为生存期的预测指标;ERCC与BRCA-1的表达具有相关性,但BRCA-1目前尚不能作为大肠癌患者铂类化疗生存期的预测指标,需进一步观察。Objective To evaluate the relationship between the BRCA-1,ERCCmRNA expression and clinicopatho- logical paramete,prognosis in Colorectal cancer treated by platinum based chemotherapy. Methods Using the real-time quantitative ,we detected BRCA-lmRNA ,ERCC-mRNA expression level and analyzed the relation between BRCA-1, ERCCmRNA expression and clinicopathological paramete, prognosis in 54 Colorectal cancer patients. Results （1） BRCA-1 mRNA was significant correlation with Lymph node metastasis （P = 0. 037） and stage （P = 0. 034） （2） The median survival time in low BRCA-1 expression was longer than those in high expression （47.84 months Vs 35.36 months,P=0. 137） ;（3） The median survival time in high BRCA-1 expression was longer than those in low expression （32.6months Vs 9.5 months,P=0. 026）in 16 advanced Colorectal cancer pations,and TTP was longer in high BRCA- 1 expression （10.3months Vs4.3months, P= 0. 026） ; （4）ERCCmRNA was no significant correlation with clinicopatho- logical paramete ; （5） The median survival time in low ERCC expression was longer than those in high expression （49.50 months Vs 30.33 months,P=0. 014） ; （6） The median survival time in low ERCC expression was longer than in high expression （41.1months Vs 20.7 months,P=0. 018）in 16 advanced Colorectal cancer pations,and TTP was no Statistically significant~ （7）ERCCmRNA was Positive relation with BRCAqmRNA（r= 0.497 P＂d0.05）^（8） COX multivariate analysis showed that the expression level of ERCCmRNA as platinum-based chemotherapy in patients with colorectal cancer were independent predictors of prognosis. Conclusion Our study suggested that ERCC was an predic- tive marker for survival of the patients with Colorectal cancer receiving platinum-based, but BRCA-1 was not an predic- tive marker Currently.

关 键 词：BRCA-1 ERCC大肠癌 生存时间 铂类 化疗 

分 类 号：R735.34[医药卫生—肿瘤]